Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gibberish!!!
"999" is taking time to produce a massive amount of (mis)information, AND he doesn't own a single share in Pluristem! He seem unable to leave. What a fraud!!!!
I'm afraid the gadfly's attempt to "help" you misfired.
You never know what causes a temporary up blip. You might be right but I still think that any success for the general notion of cell based therapeutics is good for us. There is a lot of space for multiple companies in this therapeutic arena and I hope and expect that Pluristem will be one of the success stories.
Buy(out) rumors come and go, and the effect is temporary, until the next rumor. The only thing I rely on is success stories for the technology, from Pluristem and others.
Here's why we're up!
The news is not about Pluristem, BUT it's one more strong indication that stem cells have a tremendous potential. As I always said, any proof of concept, even if not done by Pluristem is very positive for us.
https://www.jpost.com/health-science/10-serious-covid-patients-given-israeli-drug-leave-hospital-in-one-day-669564
The company, Bonus BioGroup, presented the preliminary findings of its Phase I/II trial to peers at the International Society for Cell & Gene Therapy conference in New Orleans last week and shared the results in a statement released to the Tel Aviv Stock Exchange.
Bonus’s MesenCure, which consists of activated Mesenchymal Stromal Cells (MSCs) that are isolated from the adipose tissue of healthy donors, was found to reduce inflammation and alleviate respiratory and other symptoms in patients suffering from life-threatening respiratory distress brought on by COVID-19.
“So far, the results of the treatment with the drug MesenCure are extremely impressive and an improvement over the results of other treatments,” said Dr. Shadi Hamoud, principal investigator in the clinical trial and deputy director of the Department of Internal Medicine E at Rambam.
The "best" 999 has:
A monomaniacal, repetition of the same fantastical gibberish that he's been dumping on this board for years. Mostly on Pluristem and occasionally on yours truly. He knows nothing about Pluristem and the same about my investment in the company.
The pathetic "assless" one persists (about the "LMAO", doesn't that hurt after a while?) . When is his mommy going to kick him out of the basement. Maybe when she gets tired of emptying his chamber pot.
Checkout ClayTrader!
If you enjoy nonsensical, incomprehensible, mumbo-jumbo! Redolent with the stench of the huckster. Given that there's no action item associated with the verbiage, it's quite harmless.